NFKB1 and autoimmune uveitis: Targeted therapies aimed at these pathways, such as JAK inhibitors and NF-κB modulators, enable precise suppression of excessive inflammatory activity, offering new treatment options for patients with autoimmune uveitis who do not respond to conventional medications [120].